ACM
CELG

Adalta Capital Management’s Celgene Corp CELG Stock Holding History

Adalta Capital Management’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,665
Closed -$238K – 87
2018
Q3 		$238K Buy
+2,665
New +$236K 0.17% 71

Other funds holding CELG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adalta Capital Management's CELG Position: Q4 2018 in Review

Adalta Capital Management sold out of Celgene Corp (CELG) in Q4 2018, closing a stake of 2,665 shares — an estimated $238K sold.

Adalta Capital Management first reported a position in CELG in Q3 2018 and held it in 1 quarter. The position peaked at $238K in Q3 2018. 1,317 funds tracked by Wall St. Rank hold CELG as of Q4 2018.

  • Adalta Capital Management reported no remaining Celgene Corp position as of Q4 2018 after selling out during the quarter.
  • Adalta Capital Management sold 2,665 Celgene Corp shares in Q4 2018, an estimated $238K.
  • Adalta Capital Management first reported a position in Celgene Corp in Q3 2018 and held it in 1 quarter.
  • Adalta Capital Management's Celgene Corp position peaked at $238K in Q3 2018.
  • 1,317 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2018.

Based on Adalta Capital Management's 13F filing for Q4 2018, filed 15 Feb 2019.